Subscribe To
OBSV / ObsEva SA (OBSV) Reports Q3 Loss, Lags Revenue Estimates
OBSV News
By InvestorPlace
March 3, 2023
Why Is ObsEva (OBSV) Stock Up 93% Today?
ObsEva (NASDAQ: OBSV ) stock is taking off on Friday as investors react to insider buying at the clinical-stage biopharmaceutical company. Ernest Loum more_horizontal
By InvestorPlace
February 27, 2023
Why Is ObsEva (OBSV) Stock Up 61% Today?
ObsEva (NASDAQ: OBSV ) stock is bouncing back on Monday after the company's stock underwent a major dip during the prior day of trading. That crash sa more_horizontal
By InvestorPlace
February 24, 2023
Why ObsEva (OBSV) Stock Is Down 36% Today
ObsEva (NASDAQ: OBSV ) is trending on social media, and OBSV stock is tumbling 36% to 10.85 cents. The Swiss biopharmaceutical company announced that more_horizontal
By Zacks Investment Research
December 1, 2022
ObsEva SA (OBSV) Reports Q3 Loss, Lags Revenue Estimates
ObsEva SA (OBSV) delivered earnings and revenue surprises of 7.14% and 100%, respectively, for the quarter ended September 2022. Do the numbers hold c more_horizontal
By Zacks Investment Research
August 3, 2022
All You Need to Know About ObsEva SA (OBSV) Rating Upgrade to Buy
ObsEva SA (OBSV) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the more_horizontal
By InvestorPlace
July 27, 2022
Why Is ObsEva (OBSV) Stock Down 70% Today?
Biopharmaceutical company ObsEva (NASDAQ: OBSV ) is trending today, but not necessarily in a good way. The company issued a corporate update press rel more_horizontal
By Zacks Investment Research
June 17, 2022
ObsEva's (OBSV) Yselty Gets EU Nod to Treat Uterine Fibroids
ObsEva's (OBSV) Yselty receives its first marketing approval in the European Union for the treatment of uterine fibroids in adult women. Shares were u more_horizontal
By GlobeNewsWire
May 12, 2022
ObsEva to Host Conference Call and Webcast to Discuss First Quarter 2022 Financial Results and Provide Business Update
GENEVA, Switzerland – May 1 2 , 2022 – ObsEva SA (NASDAQ: OBSV; SIX: OBSN), a biopharmaceutical company developing and commercializing novel thera more_horizontal